Logotype for ICU Medical Inc

ICU Medical (ICUI) Q4 2011 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for ICU Medical Inc

Q4 2011 earnings summary

6 Nov, 2026

Executive summary

  • FY11 revenue rose 7% to a record $302.2M; diluted EPS was $3.15 reported and $2.59 excluding the Orbit sale gain.

  • Growth came from CLAVE, oncology, TEGO and international sales; critical care declined amid competition and pricing pressure.

  • Year-end cash, cash equivalents and investment securities totaled $160.0M, with no debt; operating cash flow reached a record $64.5M.

Financial highlights

  • Revenue was $302.2M vs. $283.0M in FY10; operating income was $65.2M vs. $47.7M, and net income was $44.7M vs. $29.9M.

  • Gross profit was $142.4M vs. $129.0M; net income includes a $14.2M gain on the Orbit asset sale and a $2.5M legal settlement benefit.

  • Excluding the Orbit sale gain, FY11 net income was a record $36.7M, or $2.59 diluted EPS.

  • Operating cash flow increased to $64.5M from $33.1M; cash and investment securities rose to $160.0M from $93.4M.

Outlook and guidance

  • FY12 revenue expectations: modest growth in domestic sales to Hospira, other domestic sales, and infusion therapy; significant oncology growth; lower critical care sales; moderate international growth.

  • FY12 SG&A expected at 26.5%–27.0% of revenue; R&D at 2.5%–3.0%; effective tax rate at ~35%.

  • FY12 capital expenditures estimated at $13M–$18M, primarily for U.S. manufacturing equipment and molds and global IT.

  • Slovakia plant was operating at 35% capacity at year-end; capacity utilization was expected to improve through 2012.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from ICU Medical